The Grifols family has entrusted the pharmaceutical group’s management to Thomas Glanzmann, who has been named chief executive officer in a notice sent to CNMV. Víctor Grifols Deu remains the Chief Operating Officer, and Ramón Grifols continues as Corporate General Manager. This move marks the entrance of an external leader into the executive suite, a step previously taken when Steven F. Mayer was appointed chairman in September 2022.
Under this arrangement, Víctor Grifols will oversee daily operations in his capacity as Chief Operating Officer. All operational functions will report to him, and he will remain a board member. In parallel, Raimon Grifols, the company’s current vice president, will focus on optimizing the value of affiliates and corporate associations, stepping into the role of corporate CEO to lead major corporate initiatives alongside the Grifols group.
The changes are framed by the company as a means to accelerate the execution of its strategic plan and align with the broader restructuring that Grifols has been pursuing through the creation of dedicated business units. Since February 2023, Grifols has advanced an operational improvement program designed to boost competitiveness, trim the cost base, and enhance efficiency and organizational effectiveness across the group.
Restructuring of decision making
The organization has established a single executive figure to centralize its most strategic decisions. The company created the Senior Executive Leadership Team (SELT) two months ago and has since implemented functional changes at the top of the leadership pyramid. This shift aims to streamline governance and accelerate decision cycles in a fast-moving, competitive market.
“These changes position the group for the next growth phase and are intended to deliver stronger results while reinforcing our commitments to all stakeholders,” stated Glanzmann, who holds the positions of Chairman and Chief Executive Officer of Grifols. His leadership is expected to guide the firm through the next period of expansion, ensuring alignment between short-term actions and long-term goals.
Glanzmann and his executive team will determine and execute Grifols’ strategic choices, shaping both immediate actions and longer-range plans. Their remit covers portfolio optimization, international expansion plans, and the refinement of operational structures to support scalable growth. The leadership team will continue to evaluate performance metrics and ensure that the group maintains disciplined capital allocation, financial stewardship, and risk management—elements that are essential to sustaining competitive advantage in the pharmaceutical sector. [citation: Grifols corporate communications; updated 2024.]